As I checked over my Stocks and Shares ISA portfolio at the weekend, two shares stood out. Not in a good way, unfortunately. One FTSE 100 stock has plunged by 48% since I invested (twice!) last year, while the other is down 61%. I’m now left wondering whether I should cut my losses and invest elsewhere. ...
motleyfooluklse:ocdousx:dna
In a world where biotechnology is always becoming more sophisticated, manufacturing-oriented biotech businesses like Ginkgo Bioworks (NYSE: DNA) are upping the ante by becoming larger and more capable of handling complex asks from customers. But doing that requires a lot of capital expenditures, and ...
motleyfoolusx:dna
After an insane 1,882% rise in five years, Nvidia has been an incredible growth stock. I’ve been hunting for shares that could replicate this kind of performance. Here’s one potential contender — down 48% since I first invested — that I’d consider buying at $1 today. Programmable DNA The stock is Ginkgo ...
motleyfoolukusx:dna
Sometimes it pays to team up. That's what Novo Nordisk (NYSE: NVO) and Ginkgo Bioworks (NYSE: DNA) decided to do April 10 when they launched a new manufacturing collaboration that could benefit both companies. Details about the financial terms of their team-up are scarce, but there are at least a few ...
motleyfoolusx:nvousx:dna
